What Makes Some Tumor Peptides Trigger an Immune Attack While Others Don't | Research

The takeaway

The central region (positions 4-8) of tumor-derived peptides is the key determinant of whether they can activate T-cells, forming more stable and flexible complexes with immune receptors than non-immunogenic peptides.

Positions p4-p8 are critical
The central amino acid positions in tumor-derived peptides that determine whether T-cell receptors will engage and trigger an immune response

What the researchers found

Analysis of 38 T-cell epitopes and 144 non-epitopes revealed that immunogenic peptides have strong amino acid preferences at central positions p4-p8, while non-epitopes do not.

Molecular dynamics simulations (100 ns) of representative epitope and non-epitope complexes with TCR-peptide-HLA showed:

- The immunogenic epitope formed a more stable complex with greater flexibility, supporting an induced-fit recognition mechanism

- It established a broader and longer-lasting network of hydrogen bonds and π interactions across positions p4-p8

- The non-epitope engaged the TCR at only two positions, explaining its inability to trigger a full immune response

These findings identify the peptide's central region as the primary driver of TCR engagement and immunogenicity.

Why it matters

Cancer immunotherapy depends on identifying which tumor-derived peptides can actually trigger an immune attack. Currently, many predicted neoantigens fail to activate T-cells in practice. Understanding the molecular rules that distinguish immunogenic from non-immunogenic peptides could dramatically improve the success rate of personalized cancer vaccines and help design more effective peptide-based immunotherapies.

How the study worked

The researchers compiled two datasets of nine-amino-acid (nonamer) peptides: 38 known T-cell epitopes and 144 non-epitopes that bind HLA but don't activate T-cells. Sequence logo analysis compared amino acid preferences at each position. A representative epitope-non-epitope pair was selected for structural modeling using TCR-peptide-HLA complex structures, followed by 100 nanosecond molecular dynamics simulations to assess binding stability, flexibility, and interaction networks.

What this study cannot tell us

The study used computational methods (molecular dynamics simulations) rather than experimental validation of the structural findings. The analysis was limited to nonamer peptides binding to specific HLA types, so the findings may not generalize to all peptide lengths and HLA alleles. The datasets were relatively small (38 epitopes, 144 non-epitopes). Only one representative pair was selected for detailed MD simulation, which may not capture the full diversity of binding mechanisms.

How to read the evidence

This is a computational study using sequence analysis and molecular dynamics simulations. While the methods are rigorous and the datasets are well-defined, the findings are predictions that require experimental validation. The evidence level is preclinical and hypothesis-generating.

When this study was published

Published in 2025, this study applies current computational techniques to a fundamental question in tumor immunology that is directly relevant to the rapidly growing field of personalized cancer vaccines.

The bigger picture

Personalized cancer vaccines are one of the most promising frontiers in oncology, with companies racing to develop neoantigen-based therapies. The bottleneck is prediction accuracy — which tumor mutations will produce peptides the immune system can actually respond to. This study provides structural and molecular insights that could improve computational neoantigen prediction algorithms, potentially increasing the efficacy of next-generation cancer vaccines.

Questions still open

Can the amino acid preferences identified at positions p4-p8 be incorporated into neoantigen prediction algorithms to improve cancer vaccine design?
Does the induced-fit flexibility mechanism apply to peptides of different lengths and HLA subtypes?
How well do these computational findings predict actual T-cell activation in experimental immunogenicity assays?

Common questions

Why can't all tumor peptides trigger an immune response?

For a tumor peptide to activate the immune system, it must do two things: bind to an HLA molecule on the cell surface, and then engage a T-cell receptor strongly enough to trigger T-cell activation. Many peptides accomplish the first step but fail the second. This study shows that the peptide's central region (positions 4-8) determines whether it can form the stable, flexible interactions with T-cell receptors needed for activation.

How could this research improve cancer treatments?

Personalized cancer vaccines work by teaching the immune system to recognize peptides unique to a patient's tumor. The challenge is predicting which tumor peptides will actually trigger an immune response. By identifying the molecular features that make peptides immunogenic, this research could help scientists choose better vaccine targets, leading to more effective personalized cancer therapies.

Read the original research

Molecular Insights into Tumor Immunogenicity.

Current issues in molecular biology, 47(8)

View on PubMed ↗Publisher’s paper ↗

Citation

Doytchinova, Irini; Sotirov, Stanislav; Dimitrov, Ivan. (2025). Molecular Insights into Tumor Immunogenicity.. Current issues in molecular biology, 47(8). https://doi.org/10.3390/cimb47080641